Skip to Content
E. Jason Abel, MD, FACS

Contact Dr. Abel

E-mail:
abel@urology.wisc.edu

Phone:
(608) 263-4563

Mail:
UW Medical Foundation Centennial Building
1685 Highland Ave
Madison, WI 53705-2281

E. Jason Abel, MD, FACS

Associate Professor
Department of Urology

Education

  • BS, Zoology; BA, Molecular Biology, University of Texas at Austin, 1998
  • MD, The University of Texas at Houston Medical School, 2003
  • Residency, University of Utah Division of Urology, Salt Lake City, UT, 2008
  • Fellowship, Urologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2010

Dr. Abel specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

Clinical Specialties

Dr. Abel is certified by the American Board of Urology. He performs open and laparoscopic surgery including surgery using the daVinci robot. Dr Abel’s philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Research Interests

Dr. Abel conducts clinical, translational, and basic research in urologic oncology. Clinical and translational interests include improving patient outcomes after complex urologic surgery, improving prognostic ability for patient decision making, and multidisciplinary care of kidney cancer.

Dr. Abel serves on the board of directors for the Society of Urologic Oncology (SUO) Clinical Trials Consortium.

Funding/Grants
  • Role of NFXB/HIF2A Axis in Renal Cell Carcinoma Progression
    Funding Agency: National Institutes of Health (NIH); National Cancer Institute (NCI) Career Development Award 1K08CA178168-01
    Principal Investigator(s): E. Jason Abel, MD, FACS
    More Information

Recent Publications
  • Best SL, Blute M, Lane B, Abel EJ. Surgical Treatment of 4-10 cm Renal-Cell Carcinoma: A Survey of the Lions and Gazelles. J. Endourol. 2017 Mar 22.
    [PubMed ID: 28326796]
    More Information
  • Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy Renal Cell Carcinoma Patients with Venous Tumor Thrombus. J. Urol. 2017 Mar 04.
    [PubMed ID: 28268170]
    More Information
  • Blute ML, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, Jarrard DF. Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS ONE 2017; 12(2):e0172048.
    [PubMed ID: 28234906, PMCID: 5325224]
    More Information
  • Wells SA, Wong VK, Wittmann TA, Lubner MG, Best SL, Ziemlewicz TJ, Hinshaw JL, Lee FT, Abel EJ. Renal mass biopsy and thermal ablation: should biopsy be performed before or during the ablation procedure? Abdom Radiol (NY) 2017 Feb 09.
    [PubMed ID: 28184961]
    More Information
  • Klapperich ME, Abel EJ, Ziemlewicz TJ, Best S, Lubner MG, Nakada SY, Hinshaw JL, Brace CL, Lee FT, Wells SA. Effect of Tumor Complexity and Technique on Efficacy and Complications after Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. Radiology 2017 Jan 11; ():160592.
    [PubMed ID: 28076721]
    More Information
  • Wittmann TA, Abel EJ. Percutaneous biopsy in large, locally advanced or metastatic renal tumors. Urol. Oncol. 2017 Mar; 35(3):87-91.
    [PubMed ID: 27889280]
    More Information
  • Blute ML, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology 2017 Feb; 100():139-144.
    [PubMed ID: 27667156]
    More Information
  • Blute ML, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol 2016 Sep 15.
    [PubMed ID: 27631325]
    More Information
  • Richards KA, Abel EJ. Surveillance following surgery for nonmetastatic renal cell carcinoma. Curr Opin Urol 2016 Sep; 26(5):432-8.
    [PubMed ID: 27467135]
    More Information
  • Abel EJ. Editorial Comment. Urology 2016 Oct; 96():113.
    [PubMed ID: 27561850]
    More Information


webmaster@surgery.wisc.edu Copyright © 2017 The Board of Regents of the University of Wisconsin System